Plant Name: Crotalaria pallida
Taxonomic Information:
Plant ID: NPO9646
Plant Latin Name: Crotalaria pallida
Taxonomy Genus: Crotalaria
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
3830
Plant-of-the-World-Online:
322608-2
Used in Medicines:
Country/Region:
Kenya; Tanzania; Rwanda; IndiaTraditional Medicine System:
Indian FolkGeographical Distribution:
Brazil; Madagascar; Bangladesh; Sudan; Guinea; Mali; Costa Rica; Cambodia; Malawi; Ethiopia; Rwanda; Peru; Laos; Nigeria; Bolivia; Cameroon; Cote d'Ivoire; Ecuador; Benin; Ghana; Australia; Vanuatu; Cuba; Venezuela; Zambia; Papua New Guinea; Burkina Faso; Togo; Trinidad and Tobago; Zimbabwe; China; Thailand; Belize; Sierra Leone; Liberia; Nepal; Swaziland; Pakistan; Gambia; Tanzania; Indonesia; New Caledonia; Mauritius; Sri Lanka; Vietnam; Gabon; Guinea-Bissau; Guyana; Honduras; Taiwan; Jamaica; Seychelles; Angola; Myanmar; Chad; Equatorial Guinea; Mexico; India; South Africa; Uganda; Senegal; Congo; Mozambique; Colombia; Burundi; Kenya; Niger; Nicaragua
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ACHE; | |
| EBP; HSD17B10; HSD17B1; NOS2; | |
| CSNK2A1; | |
| ESR2; | |
| KDM4E; | |
| NFKB1; | |
| EBPL; THPO; SIGMAR1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | EBP | 3-beta-hydroxysteroid-delta(8),delta(7)-isomerase | Q15125 | CHEMBL4931 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | NOS2 | Nitric oxide synthase, inducible | P35228 | CHEMBL4481 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | EBPL | Emopamil-binding protein-like | Q9BY08 | CHEMBL2311238 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.211E-12 | 1.305E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.306E-10 | 1.440E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.772E-10 | 2.729E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, NOS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.374E-09 | 6.680E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, NOS2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.769E-08 | 1.053E-04 | CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 4.290E-07 | 4.462E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, EBP, EBPL, SIGMAR1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.457E-07 | 7.060E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0047750; cholestenol delta-isomerase activity | 7.290E-07 | 7.060E-04 | EBP, EBPL |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.919E-07 | 8.999E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.332E-06 | 2.134E-03 | CYP19A1, CYP1A1, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 4.095E-06 | 2.410E-03 | CYP19A1, CYP1B1, EBP, EBPL |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.370E-06 | 2.504E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0032451; demethylase activity | 5.074E-06 | 2.695E-03 | CYP1A1, CYP1A2, KDM4E |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.091E-05 | 5.166E-03 | CYP1A2, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.527E-05 | 6.786E-03 | CYP1A2, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 1.527E-05 | 6.786E-03 | CYP1A1, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.035E-05 | 8.522E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.036E-09 | 8.288E-08 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 8.030E-08 | 3.212E-06 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.750E-07 | 9.999E-06 | CYP2D6, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.943E-06 | 9.885E-05 | CYP1A2, CYP1A1, CYP1B1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 3.859E-05 | 5.778E-04 | EBP, NOS2, HSD17B1, CYP1A2, CYP1A1, CYP19A1, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.334E-05 | 5.778E-04 | CYP1A2, CYP1A1, CYP1B1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; NFKB1; ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | EBP; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | NOS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | NOS2; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | NOS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | NOS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | NOS2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; NOS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic kidney disease | E11.22 | NOS2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | NOS2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Endotoxic shock | R57.8 | NOS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
